Apollomics Inc (APLM) Stock Analysis
Verdict: AVOID
Severe liquidity distress with under 4 months of cash runway creates extreme dilution risk despite recent technical price momentum.
Investment score: 27/100
Analysis as of
Is Apollomics Inc stock worth reviewing? The TradeMates thesis
Apollomics faces an acute cash crunch with $3.28M in cash against $10.37M annual burn, implying under 4 months of runway before mandatory dilution.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 60/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 40/100 (weight 10%)
- Risk-Adjusted Return: 15/100 (weight 15%)
Apollomics Inc opportunities and risks
What speaks for APLM
- Clinical progress in lead drug candidate APL-101 (Vebreltinib)
What speaks against APLM
- Imminent cash exhaustion and severe dilution risk
Frequently asked questions about Apollomics Inc (APLM)
Is APLM stock a good investment?
The TradeMates model rates Apollomics Inc as AVOID with an investment score of 27/100. Apollomics faces an acute cash crunch with $3.28M in cash against $10.37M annual burn, implying under 4 months of runway before mandatory dilution. This is algorithmic model output, not personal investment advice.
Is APLM stock a buy?
The TradeMates model verdict for APLM is AVOID with an investment score of 27/100. Treat this as a model signal to review, not a personal buy recommendation.